Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sublivac Fix Mite mixture is a sublingual immunotherapy (SLIT) developed by HAL Allergy for the treatment of allergic rhinitis and rhinoconjunctivitis caused by a sensitization to house dust mite (HDM) allergens. It is a liquid preparation of standardized house dust mite allergen extracts administered as drops under the tongue. The therapy works by gradually exposing the immune system to increasing amounts of the allergen, which can desensitize the patient and alter the natural course of the allergic disease, potentially reducing symptoms and the need for other medications over the long term. Clinical trials have been conducted to determine the optimal dosage, safety, and tolerability of different concentrations of the mixture.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on house dust mite allergen extract (HAL Allergy Group).